Avillion LLP, a drug development company focused on the co-development and financing of pharmaceutical candidates, has announced the appointment of Dr Anders Gersel Pedersen as a Non-Executive Director of Bond 2 Development 2 GP, the General Partner of Bond Avillion 2, the Avillion entity that enters into the co-development agreements with pharma partners.
Iteos Therapeutics SA, a privately-held biotechnology company developing novel cancer immunotherapies, last week announced the appointment of Matthew Call as its Chief Operating Officer. Matthew will also be responsible for business development.
Immunic, Inc., a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced the appointment of Sanjay S. Patel, CFA, as Chief Financial Officer, effective July 15, 2019. Mr. Patel replaces Tamara A. Seymour, who has served as the companys Interim Chief Financial Officer since April 26, 2019.
Pieris Pharmaceuticals, Inc. today announced that Maya R. Said, Sc.D., has joined the Companys Board of Directors.
Healx, a Cambridge, UK, technology company developing treatments for rare diseases, today announces the appointment of Dr Neil Thompson, PhD, as Chief Scientific Officer (CSO).
Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical Company active in the discovery and development of T-cell redirecting cancer immunotherapies, today announced that Harpreet Singh has been appointed the Companys Chief Executive Officer (CEO).
Zelluna Immunotherapy, a biotechnology company specializing in T-cell receptor (TCR) immunotherapies, announced the appointment of Jens-Peter Marschner as chief medical officer (CMO) at the end of June.
Swedenbio’s Board has appointed Helena Strigård as the new CEO. Strigård will take up the position on September 1 and replace Jonas Ekstrand,
Teckro today announced five significant appointments to its leadership team. The hires follow Teckros Series C funding announcement in February, featuring investment from major US venture capital firms. To date, Teckro has raised $43 million.
Germany-based MorphoSys AG announced that its Supervisory Board has today appointed Jean-Paul Kress, M.D., as its new Chief Executive Officer. The appointment will take effect on September 1, 2019.